5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer - NCT06179069

• DOI: 10.1016/j.ejca.2024.114534
• Publication Date: 2024-10-25T13:19:51Z
• Authors: A. Spira; A. Dowlati; J. Zhao; M.R. Patel; Q. Wang; X. Dong; M. Gutierrez; Z. Wang; G. Dy; X. Liu; Y. Fu; X. Shen; R. Zhou; Y.L. Wu